Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: Effects on lipid metabolism

Contraception

Volumn 85, Issue 4, 2012, Pages 389-393

  Guazzelli, Cristina Aparecida Falbo ^a   Barreiros, Fernando Augusto ^a,b   Barbosa, Ricardo ^b   Torloni, Maria Regina ^a   Barbieri, Marcia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Contraceptive vaginal; Extended cycle; Hormonal contraceptive; Hormonal metabolic; Lipids cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PROSPECTIVE STUDY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA RING;

ADOLESCENT; ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIPID METABOLISM; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84858333276     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.08.014     Document Type: Article

References (25)

1. J.K. Williams Rationale for new oral contraceptive dosing Int J Fertil Womens Med 49 2004 30 35 [Review] (Pubitemid 38337896)
2. R.G. Edwards, and J. Cohen The recent saga of cardiovascular disease and safety of oral contraceptives Hum Reprod Update 5 1999 565 620 (Pubitemid 30034883)
3. F. Roumen, D. Apter, T. Mulders, and T. Dieben Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol Hum Reprod 16 2001 469 475 (Pubitemid 32218795)
4. P.J. Sulak, T.J. Kuehl, M. Ortiz, and B.L. Shull Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms Am J Obstet Gynecol 186 2002 1142 1149 (Pubitemid 34665050)
5. B.V. Stadel Oral contraceptives and cardiovascular diseases. First of two parts New Eng J Med 305 1981 612 619
6. B.V. Stadel Oral contraceptives and cardiovascular diseases. Second of two parts New Eng J Med 305 1981 672 677 (Pubitemid 11056136)
7. B. Kaplan Desogestrel, norgestimate, and gestodene: the newer progestins Ann Pharmacother 29 1995 736 742
8. M. Akerlund, E. Almström, S. Högstedt, and M. Nabrink Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone Acta Obstet Gynecol Scand 73 1994 136 143 (Pubitemid 24064088)
9. R.B. Machado, P. Fabrini, A.M. Cruz, E. Maia, and A.C. Bastos Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg) Contraception 70 2004 365 370 (Pubitemid 39422512)
10. I. Wiegratz, S. Stahlberg, and T. Manthey Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use Contraception 81 2010 57 61
11. M. Tuppurainen, R. Klimscheffskij, M. Venhola, and T.O. Dieben The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study Contraception 69 2004 389
12. F.A. Barreiros, C.A.F. Guazzelli, R. Barbosa, M.R. Torloni, M. Barbieri, and F.F. Araujo Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism Contraception 84 2 2011 155 159
13. World Health Organization Medical eligibility criteria for contraceptive use. Reproductive Heath and Research 4th ed. 2008 WHO Geneva
14. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
15. I. Godsland, D. Crook, and R. Simpson The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism N Engl J Med 323 1990 1375 1381
16. D. Crook, I.F. Godsland, and V. Wynn Oral contraception and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins Am J Obstet Gynecol 158 1988 1612 1620
17. D. Crook Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin Contraception 55 1997 219 224 (Pubitemid 27435167)
18. S.O. Skouby, J. Endrikat, and B. Düsterberg A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel Contraception 71 2005 111 117 (Pubitemid 40222063)
19. T. Foulon, N. Payen, and F. Laporte Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size Contraception 64 2001 11 16 (Pubitemid 32787091)
20. C.J. Timmer, and T.M. Mulders Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring Clin Pharmacokinet 39 2000 233 242
21. P.J. Barter, C.M. Ballantyne, and R. Carmena Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 259 2006 247 258
22. M.J. McQueen, S. Hawken, and X. Wang INTERHEART study investigators Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 19 372 2008 185 186
23. G. Walldius, and I. Jungner Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid modifying therapy J Intern Med 255 2004 188 205 (Pubitemid 38241363)
24. W.A. van der Steeg, I. Holme, and S.M. Boekholdt High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642 (Pubitemid 351186873)
25. L. Duvillard, G. Dautin, and E. Florentin Increased apolipoprotein AI production rate and redistribution of high-density lipoprotein size induced by estrogen plus progestin as oral contraceptive J Clin Endocrinol Metab 94 12 2009 4891 4897